Heart failure & cardiomyopathies
The Mayo ATTR-CM Score Versus Other Diagnostic Scores and Cardiac Biomarkers in Patients with Suspected Cardiac Amyloidosis
Authors' conclusion
The Mayo ATTR-CM score has a good performance in identifying patients with ATTR-CA, with also better discrimination power when compared to other scores and biomarkers.
Study context
- Population
- Consecutive patients referred to a third-level centre for suspected cardiac amyloidosis
- Participants
- 362 patients
- Comparison
- Mayo ATTR-CM score vs IWT score, AMYLI score and cardiac biomarkers
- Outcome
- Diagnostic performance (AUC) of the ATTR-CM score for ATTR-CA
Methodological detailsconsecutive patients, single third-level centre
- Consecutive patients
- Single third-level centre
Performance
As reported in the abstract
ATTR-CA vs AL-CA or no CA
| Test or model | AUC (ATTR-CA vs AL-CA or no cardiac amyloidosis (CA)) | AUC (ATTR-CA vs no CA) |
|---|---|---|
| ATTR-CM score | 0.795 (95% CI 0.747-0.842, p < 0.001) | 0.822 (95% CI 0.774-0.871, p < 0.001) |
ATTR-CM score
AUC (ATTR-CA vs AL-CA or no cardiac amyloidosis (CA))0.795 (95% CI 0.747-0.842, p < 0.001)
AUC (ATTR-CA vs no CA)0.822 (95% CI 0.774-0.871, p < 0.001)
- ATTR-CM score vs IWT and AMYLI score: P = 0.002 — ATTR-CA vs AL-CA or no CA; better with ATTR-CM
- ATTR-CM score vs IWT and AMYLI score: P = 0.270 — ATTR-CA vs no CA; not better
Further findings
ATTR-CM score AUC by EF (subgroup)
- Preserved EF: AUC
- 0.787 (95% CI 0.726-0.848, p < 0.001)
- Reduced or mildly reduced EF: AUC
- 0.790 (95% CI 0.709-0.871, p < 0.001)
Original publication
The Mayo ATTR-CM Score Versus Other Diagnostic Scores and Cardiac Biomarkers in Patients with Suspected Cardiac Amyloidosis. Eur J Heart Fail. Published 9 September 2024. doi:10.
Summarised from the published abstract; every number is checked against it